It has further been demonstrated that both CD4+ and CD8+ T cells found in the PBMCs and tumor-infiltrating lymphocytes (TILs) of melanoma patients are capable of capturing melanoma antigens, leading to enhanced tumor-specific reactivity and cytotoxicity (Eisenberg et al., 2013). The gene discussed is CD4; the disease is neoplasm.